A. Wijatyk

Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis

H. Einsele, F. Baldanti, G. Fahle, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

G. Papanicolaou, M. Boeckh, F. Marty, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

J. Kuusisto, P. Chang, O. Goker-Alpan, 2015, Drug design, development and therapy.

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.

P. Jaksch, O. Witzke, F. Saliba, 2019, The New England journal of medicine.

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

D. Underwood, A. Tolcher, M. Findeis, 2020 .

Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients

P. Jaksch, O. Witzke, F. Saliba, 2016 .

First human study of BMS747158, a novel F-18 labeled tracer for myocardial perfusion imaging

M. Phelps, H. Schelbert, J. Czernin, 2008 .

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

A. Mehta, U. Ramaswami, R. Giugliani, 2015, Molecular genetics and metabolism reports.

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

R. Schiffmann, P. Chang, Y. Lien, 2014, Orphanet Journal of Rare Diseases.

Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.

P. Chang, O. Goker-Alpan, Y. Lien, 2015, JIMD reports.